H.C. Wainwright Reiterates Buy Rating on NovaBridge Biosciences (NBP) following FDA meeting feedback
-
Brookline on NovaBridge Biosciences (NBP) Amid 10 Drop: 'Givastomig Dose Expansion Data Promising, Compares Favorably to Competition'
-
I-MAB rebrands as NovaBridge Biosciences, ticker changes to NBP

